# Akeylink

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/akeylink

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.akeylink.cn
- Latest round: Series A (Oct 16, 2025)
- Investors on record: 1

## About

Based in Shanghai, China and founded in 2021,  Fujian Guang Sheng Zhong Lin Biotechnology Co., Ltd., trading as Akeylink, focuses on the research and development of innovative drugs in the fields of antiviral and liver diseases. In October 2025, Akeylink closed a Series A funding from new investor People's Capital.
The company specializes in developing innovative software solutions designed to streamline business operations and enhance productivity across various industries. The company's flagship product is a comprehensive enterprise resource planning (ERP) system that integrates key business functions such as inventory management, financial reporting, and customer relationship management into a single platform. This system allows businesses to automate processes, improve data accuracy, and foster collaboration among departments. The company’s client base includes small to medium-sized enterprises in sectors such as manufacturing, retail, and logistics, primarily serving markets in North America, Europe, and parts of Asia. 
The company generates revenue through a subscription-based model, where clients pay for access to its software solutions on a monthly or annual basis.

## Funding rounds

- Series A, Oct 16, 2025 — People's Capital

## Investors

- People's Capital (https://capitalatlas.ai/funds/people-s-capital) — Series A